Home » Newsletters » BioWorld

BioWorld

Sep. 29, 2014

View Archived Issues

Investors hear the call, back biotechs developing ear drugs

Last month, two companies developing drugs for the ear – a fairly neglected field – went public. Read More

Week in review

Word on the street

Week in Washington

FDA approvals in August

Phase I clinical trials update: August 2014

Phase II clinical trials update: August 2014

Phase III clinical trials update: August 2014

Pharma clinical and FDA action update: August 2014

Non-U.S. clinical trials and regulatory actions: August 2014

FDA submissions, approvals & other actions: August 2014

Money raised by biotech in 2014 vs. 2013

Money raised by biotech: Jan. 1 - Sept. 25, 2014

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...